Definium’s LSD-Based Drug Lowers Anxiety in Second Successful Late-Stage Study

Definium's LSD-based drug lowers anxiety in second successful late ...

Definium, Up 190% This Year, Flies Again On LSD Win

Definium Therapeutics' synthetic LSD eased the symptoms of anxiety, the company said Monday as shares took off again.

Definium's LSD-based drug lowers anxiety in second successful late-stage study

A single 100-microgram dose of DT120, a fast-dissolving tablet of lysergide, the chemical name for the psychedelic drug LSD, reduced scores on an anxiety scale by 9.8 points after 12 weeks.

Definium’s LSD-based drug lowers anxiety in second successful late-stage study

By Kamal Choudhury and Puyaan Singh Sept 14 - Definium Therapeutics said on Monday its LSD-based treatment reduced symptoms of generalized anxiety disorder in a trial, giving the company ​a second successful late-stage study for the condition. A single...

Definium’s LSD therapy eased anxiety in second large trial

Definium is among a wave of biotechs nearing regulatory approval for psychedelic therapies, which appear to exert rapid benefits for patients.

Definium Therapeutics (DFTX) Stock Soars 20% on Successful Phase 3 Anxiety Trial Results

Definium Therapeutics (DFTX) stock rose 20% after DT120 ODT met Phase 3 endpoints for GAD treatment. NDA submission planned for H1 2027.